Elliott makes $7B all-cash bid for Athenahealth

| | Health Exec | Policy & Regulations

According to CNBC, Elliott Management made an all-cash deal for Athenahealth on Monday morning. Elliott’s bid is for $160 a share—a 27 percent premium to the Massachusetts-based healthcare technology company’s Friday afternoon price.

Athenahealth shares were up sharply in Monday trading after initial reports of a possible deal.

Elliott released a letter to Athenahealth on Monday, claiming his firm has had constructive discussions with management, "and we greatly appreciate how much time the management team, led by Jonathan, and the [b]oard have invested in evaluating our perspectives as well as the perspectives of our fellow shareholders."

Paul Singer's Elliott makes all-cash offer for Athenahealth of $160 a share

But Elliot continued, “Unfortunately, we are faced now with the stark reality that athenahealth as a public-company investment, despite all of its promise, has not worked for many years, is not working today and will not work in the future. Given athenahealth's potential, this reality is deeply frustrating."

CNBC is reporting the deal could be worth $7 billion, including debt.

Read more at the link below:

Related Content

FDA issues Class I alert on Philips ventilators after 4 injuries
Trump selects Emmy-winning TV personality Dr. Oz to head CMS
FDA issues Class I recall of infusion pump batteries due to risk of burns
When life sciences met artificial intelligence
DEA, HHS extend telehealth controlled substance prescription rule
Public health contrarian RFK Jr. nominated to HHS secretary

Around the web

Cardiovascular Business
Payment cuts and beyond: Key takeaways for cardiologists from the 2025 Medicare Physician Fee Schedule

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

AI in Healthcare
A modest proposal to rally AI regulators around a simple game plan

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”

Cardiovascular Business
FDA commissioner urges clinicians to join fight against medical misinformation

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

Design by Adaptive Theme
Trimed Popup
Trimed Popup